Viewing Study NCT07408635


Ignite Creation Date: 2026-03-26 @ 3:17 PM
Ignite Modification Date: 2026-03-29 @ 11:58 PM
Study NCT ID: NCT07408635
Status: RECRUITING
Last Update Posted: 2026-02-13
First Post: 2026-01-22
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: IBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non-Small Cell Lung Cancer
Sponsor: Shanghai Pulmonary Hospital, Shanghai, China
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module